Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2020 Jul 2

PMID 32605162

Citations 9

Authors

Yen-Ho Lai

Chih-Sheng Chiang

Chin-Hao Hsu

Hung-Wei Cheng

San-Yuan Chen

Affiliations

Soon will be listed here.

Abstract

Fucoidan, a natural sulfated polysaccharide, which can activate the immune response and lessen adverse effects, is expected to be an adjuvant agent in combination with chemotherapy. Using natural hydrophilic anticancer polysaccharides to simultaneously encapsulate hydrophobic anticancer drugs is feasible, and a reduced side effect can be achieved to amplify the therapeutic efficacy. In this study, a novel type of fucoidan-PLGA nanocarrier (FPN-DTX) was developed for the encapsulation of the hydrophobic anticancer drug, docetaxel (DTX), as a drug delivery system. From the comparison between FPN-DTX and the PLGA particles without fucoidan (PLGA-DTX), FPNs-DTX with fucoidan were highly stable with smaller sizes and dispersed well without aggregations in an aqueous environment. The drug loading and release can be further modified by modulating relative ratios of Fucoidan (Fu) to PLGA. The (FPN 3-DTX) nanoparticles with a 10:3 ratio of Fu:PLGA displayed uniform particle size with higher encapsulation efficiency than PLGA NPs and sustained drug release ability. The biocompatible fucoidan-PLGA nanoparticles displayed low cytotoxicity without drug loading after incubation with MDA-MB-231 triple-negative breast cancer cells. Despite lower cellular uptake than that of PLGA-DTX due to a higher degree of negative zeta potential and hydrophilicity, FPN 3-DTX effectively exerted better anticancer ability, so FPN 3-DTX can serve as a competent drug delivery system.

Citing Articles

Fabrication of lipid-modified drug nanocrystals loaded injectable hydrogel for breast cancer therapy.

Kumar M, Jha A, Goswami P, Srivastava R, Manjit M, Bharti K Discov Nano. 2025; 20(1):30.

PMID: 39937325 PMC: 11822163. DOI: 10.1186/s11671-025-04195-w.

Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.

Wang R, Huang X, Chen X, Zhang Y ACS Biomater Sci Eng. 2024; 10(6):3568-3598.

PMID: 38815129 PMC: 11167598. DOI: 10.1021/acsbiomaterials.4c00108.

Novel Fucoidan Pharmaceutical Formulations and Their Potential Application in Oncology-A Review.

Zahariev N, Katsarov P, Lukova P, Pilicheva B Polymers (Basel). 2023; 15(15).

PMID: 37571136 PMC: 10421178. DOI: 10.3390/polym15153242.

Nano-Sized Fucoidan Interpolyelectrolyte Complexes: Recent Advances in Design and Prospects for Biomedical Applications.

Dubashynskaya N, Gasilova E, Skorik Y Int J Mol Sci. 2023; 24(3).

PMID: 36768936 PMC: 9916530. DOI: 10.3390/ijms24032615.

Insight into Fucoidan-Based PEGylated PLGA Nanoparticles Encapsulating Methyl Anthranilic Acid: In Vitro Evaluation and In Vivo Anti-Inflammatory Study.

Abdelkader D, Elekhnawy E, Negm W, El-Masry T, Almukainzi M, Zayed A Mar Drugs. 2022; 20(11).

PMID: 36355017 PMC: 9693061. DOI: 10.3390/md20110694.

References

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

Gharib R, Greige-Gerges H, Fourmentin S, Charcosset C, Auezova L . Liposomes incorporating cyclodextrin-drug inclusion complexes: Current state of knowledge. Carbohydr Polym. 2015; 129:175-86. DOI: 10.1016/j.carbpol.2015.04.048. View

Anastyuk S, Shevchenko N, Ermakova S, Vishchuk O, Nazarenko E, Dmitrenok P . Anticancer activity in vitro of a fucoidan from the brown alga Fucus evanescens and its low-molecular fragments, structurally characterized by tandem mass-spectrometry. Carbohydr Polym. 2021; 87(1):186-194. DOI: 10.1016/j.carbpol.2011.07.036. View

Yu T, Malugin A, Ghandehari H . Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano. 2011; 5(7):5717-28. PMC: 3238493. DOI: 10.1021/nn2013904. View

van Weelden G, Bobinski M, Okla K, Van Weelden W, Romano A, Pijnenborg J . Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms. Mar Drugs. 2019; 17(1). PMC: 6356449. DOI: 10.3390/md17010032. View

Cardoso M, Costa R, Mano J . Marine Origin Polysaccharides in Drug Delivery Systems. Mar Drugs. 2016; 14(2). PMC: 4771987. DOI: 10.3390/md14020034. View

Ikeguchi M, Yamamoto M, Arai Y, Maeta Y, Ashida K, Katano K . Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. Oncol Lett. 2012; 2(2):319-322. PMC: 3410608. DOI: 10.3892/ol.2011.254. View

Burchell S, Iniaghe L, Zhang J, Tang J . Fucoidan from Fucus vesiculosus Fails to Improve Outcomes Following Intracerebral Hemorrhage in Mice. Acta Neurochir Suppl. 2015; 121:191-8. DOI: 10.1007/978-3-319-18497-5_34. View

Lila A, Ishida T . Liposomal Delivery Systems: Design Optimization and Current Applications. Biol Pharm Bull. 2017; 40(1):1-10. DOI: 10.1248/bpb.b16-00624. View

10.

Ellouali M, Sinquin C, Boisson-Vidal C . Relationship between sulfate groups and biological activities of fucans. Thromb Res. 2001; 100(5):453-9. DOI: 10.1016/s0049-3848(00)00338-8. View

11.

Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H . Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol. 2002; 65(2):173-9. DOI: 10.1016/s0006-2952(02)01478-8. View

12.

Pozharitskaya O, Obluchinskaya E, Shikov A . Mechanisms of Bioactivities of Fucoidan from the Brown Seaweed L. of the Barents Sea. Mar Drugs. 2020; 18(5). PMC: 7281726. DOI: 10.3390/md18050275. View

13.

Maeda H, Bharate G, Daruwalla J . Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2008; 71(3):409-19. DOI: 10.1016/j.ejpb.2008.11.010. View

14.

Sun T, Zhang Y, Pang B, Hyun D, Yang M, Xia Y . Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(46):12320-64. DOI: 10.1002/anie.201403036. View

15.

Keum C, Noh Y, Baek J, Lim J, Hwang C, Na Y . Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid. Int J Nanomedicine. 2011; 6:2225-34. PMC: 3215163. DOI: 10.2147/IJN.S24547. View

16.

Bowerman C, Byrne J, Chu K, Schorzman A, Keeler A, Sherwood C . Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Lett. 2016; 17(1):242-248. PMC: 5404392. DOI: 10.1021/acs.nanolett.6b03971. View

17.

Kalaria D, Sharma G, Beniwal V, Kumar M . Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2008; 26(3):492-501. DOI: 10.1007/s11095-008-9763-4. View

18.

Hong S, Kim S, Lim S . Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes. Int J Pharm. 2015; 483(1-2):142-50. DOI: 10.1016/j.ijpharm.2015.02.013. View

19.

Badran M, Alomrani A, Harisa G, Ashour A, Kumar A, Yassin A . Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability. Biomed Pharmacother. 2018; 106:1461-1468. DOI: 10.1016/j.biopha.2018.07.102. View

20.

Nagamine T, Nakazato K, Tomioka S, Iha M, Nakajima K . Intestinal absorption of fucoidan extracted from the brown seaweed, Cladosiphon okamuranus. Mar Drugs. 2014; 13(1):48-64. PMC: 4306924. DOI: 10.3390/md13010048. View